All News
Filter News
Found 3,193 articles
-
Cerecor Closes Deal to Sell Pediatric Portfolio
11/4/2019
Cerecor Inc. announced that it has closed the sale of its pediatric portfolio of assets with AYTU BioScience, Inc. in a deal valued in excess of $43 million including the assumption of various liabilities and product-related obligations.
-
vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update
10/30/2019
SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled
-
What is the best way to prevent or even reverse Alzheimer’s disease? That’s the question at the top of many researchers’ minds, especially given all of the recent large Phase 3 failures involving beta-amyloid targeting drugs, the most pursued target to date. This is troubling but not entirely sho...
-
Clinical Catch-Up: October 21-25
10/28/2019
Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look. -
Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
10/28/2019
Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the milestone activation of 25 sites for its pivotal Phase 3 clinical trial (ARMADA 2000) of CPI-613® (devimistat) in patients with relapsed or refractory acute myeloid leukemia (AML).
-
U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney Injury
10/28/2019
Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of ASP1128 for patients at increased risk of developing moderate to severe acute kidney injury after coronary artery bypass and/or valve surgery.
-
Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome
10/25/2019
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced positive new data for its investigational drug, FINTEPLA® (ZX008, fenfluramine), for the treatment of seizures associated with Dravet syndrome
-
Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer
10/24/2019
Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, announced that the Phase 3 clinical trial of CPI-613® for patients with metastatic pancreatic cancer is now active in four sites in South Korea.
-
Clene Nanomedicine Presents New Neuroprotection Data in Parkinson's Disease with Lead Nanocatalytic Therapeutic, CNM-Au8
10/24/2019
Clene Nanomedicine, Inc. announced the presentation of new preclinical neuroprotection data in multiple Parkinson's disease models at the 2019 Society for Neuroscience Annual Meeting.
-
CohBar to Announce 2019 Third Quarter Financial Results and Provide Business Update on November 6, 2019
10/24/2019
CohBar, Inc. announced that the company will release its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019.
-
CohBar Expands Board with Biotech Veteran Misha Petkevich
10/23/2019
CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, announced the appointment of Misha Petkevich to its Board of Directors.
-
Alexion Reports Third Quarter 2019 Results
10/23/2019
Alexion Pharmaceuticals, Inc. announced financial results for the third quarter of 2019.
-
Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1 Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo
10/22/2019
Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today announced preclinical data demonstrating that small molecule inhibitors of SARM1 protect axons in both in vitro and in vivo models of axonal degeneration.
-
Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)
10/22/2019
mRNA-3927 is Moderna’s second rare disease program to receive Fast Track designation
-
BERG Collaboration Identifies Novel Mechanism Of Action Of Redox Regulation By BPM 31510 In Models Of Glioblastoma
10/22/2019
In vivo and in vitro studies of BPM 31510 demonstrate its effect on the survival of preclinical glioblastoma models through the induction of oxidative stress
-
Cirius Therapeutics' Phase 2b Data of MSDC-0602K for the Treatment of NASH Accepted as a Late-Breaking Oral Presentation at The Liver Meeting
10/21/2019
Cirius Therapeutics, a clinical stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, announced today that results of EMMINENCE, its Phase 2b clinical trial of MSDC-0602K for the treatment of NASH, will be presented at The Liver Meeting® in a late-breaking oral presentation.
-
Reenie McCarthy, chief executive officer of Stealth Biotherapeutics, has seen first-hand the negative impact of mitochondrial diseases, including watching an athlete decline from being an Olympic-level rower to becoming wheelchair-bound.
-
Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia
10/17/2019
Minoryx Therapeutics announces that its lead drug candidate, leriglitazone (MIN-102), has been granted Orphan Drug Designation in Friedreich’s Ataxia by the US Food and Drug Administration (FDA).
-
Poxel Announces Participation at the H.C. Wainwright 3rd Annual NASH Investor Conference
10/17/2019
POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be featured as a presenting company at the H.C. Wainwright 3rd Annual NASH Investor Conference and the Company will provide an overview of its two clinical stage candidates, PXL770,
-
Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma
10/17/2019
Rafael will provide the compound for the study.